0001437749-26-035713
SEC filingTPB第三季度净销售额增长27.0%至$151.1 million,但净利大幅下滑81.4%,Modern Oral高增长与营销投入拖累盈利。
| 指标 | 本期 | 去年同期 | 同比 |
|---|---|---|---|
| Net sales | $151.1 million | $119.0 million | +27.0% |
| Gross profit | $85.2 million | $70.4 million | +20.9% |
| Operating income | $9.9 million | $25.9 million | -61.9% |
| Net income attributable to Turning Point Brands, Inc. | $3.9 million | $21.1 million | -81.4% |
| Diluted EPS | $0.19 | $1.13 | -83.2% |
| Adjusted Diluted EPS | $0.41 | $1.05 | -61.0% |
| Adjusted EBITDA | $18.4 million | $31.3 million | -41.3% |
| 期间 | 指标 | 指引 | 口径 |
|---|---|---|---|
| FY 2026 | Modern Oral Gross Sales | $330-$350 million | — |
| FY 2026 | Modern Oral Net Sales | $260-$270 million | — |
| FY 2026 | Adjusted EBITDA | $70-$80 million | Non-GAAP |
增长引擎完全来自Modern Oral:Q3 Gross Sales增长114.2%至$93.9 million,Net Sales增长102.9%至$74.4 million,已占公司总净销售额49.2%;Stoker's分部净销售额增长52.0%至$113.8 million,而Zig-Zag分部净销售额下降15.5%至$37.3 million。产品结构向Modern Oral倾斜使Stoker's分部毛利率由60.2%降至56.0%,合并Gross profit虽增长20.9%至$85.2 million,但增速明显落后于收入。
利润端压力来自投入端:SG&A费用增长69.1%至$75.3 million,包含Modern Oral相关销售与营销投入及外运运费上升,直接导致Operating income下降至$9.9 million、Adjusted EBITDA下降41.3%至$18.4 million。管理层David Glazek强调对FRE与ALP的投资正在扩大分销并强化消费者互动,目标是成为快速增长的nicotine pouch品类领导者。公司重申2026全年Modern Oral Gross/Net Sales与Adjusted EBITDA指引,意味着当前的高投入被视为换取份额的阶段性成本;期末现金$251.3 million、净债务$48.7 million及总流动性$322.8 million为持续投入提供缓冲,但盈利兑现节奏仍是后续观察重点。